- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/73 - Unsubstituted amino or imino radicals
Patent holdings for IPC class C07D 213/73
Total number of patents in this class: 583
10-year publication summary
|
35
|
31
|
37
|
38
|
43
|
28
|
38
|
33
|
38
|
40
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vertex Pharmaceuticals Incorporated | 1630 |
14 |
| Bristol-myers Squibb Company | 4826 |
13 |
| Qingdao Kingagroot Chemical Compound Co., Ltd. | 181 |
11 |
| Novartis AG | 10612 |
10 |
| Northwestern University | 3457 |
10 |
| Centre National de La Recherche Scientifique | 10706 |
9 |
| Amgen Inc. | 4256 |
9 |
| Board of Regents, The University of Texas System | 5946 |
8 |
| Merck Patent GmbH | 5752 |
7 |
| Bayer Pharma AG | 1048 |
7 |
| BASF SE | 21098 |
6 |
| Bayer Cropscience AG | 1983 |
6 |
| Abbvie Inc. | 1817 |
6 |
| Arcus Biosciences, Inc. | 144 |
6 |
| Celgene Quanticel Research, Inc. | 162 |
6 |
| Oryzon Genomics S.A. | 108 |
6 |
| Vivace Therapeutics, Inc. | 31 |
6 |
| Merck Sharp & Dohme LLC | 3732 |
6 |
| F. Hoffmann-La Roche AG | 7937 |
5 |
| E. I. du Pont de Nemours and Company | 3885 |
5 |
| Other owners | 427 |